Experimental cancer treatments for advanced stages are more effective than previously thought. Some oncology practitioners believe that experimental drugs are harmful - they give false hope to patients because of its low efficiency (long anticipated effectiveness of the experimental treatment with special drugs produced in Canadian pharmacy only at the level of 4-6% of cases). Patients in the final stage of the disease should have greater access to information about the experimental treatment programs, and, accordingly, they and their families should have the right to know what their real chances, with a particular treatment strategy. Scientists believe that the involvement of cancer patients even in the early stages of clinical trials can be very useful for them. Besides, the search for a way out of the situation means continuing the fight against the disease. It is characterized by academic phrase "treatment of metastatic cancer still remains palliative, with a very low probability of complete remission and cure the disease."


Over the past decade, biomarkers and targeted therapies have been important to many of the major success stories in cancer treatment. Moreover, therapies are rarely efficient for all patients. Therefore, the inclusion of biomarker analyses into the context of clinical trials is desirable (34). The identification of biomarkers does, however, not only allow the identification of patients benefiting from a specific therapy more accurately, but also improves the understanding of how the respective therapeutics works. Consequently, within IMMOMEC we will address the identification of biomarkers predicting the course of disease (prognostic markers) and treatment outcome (predictive markers) in MCC patients.